45
Participants
Start Date
August 15, 2020
Primary Completion Date
March 15, 2022
Study Completion Date
August 3, 2022
RisperiDONE 1 MG/ML
Patients will receive two daily Risperidone 1 mg tablets (Sobhan Pharmaceutical Company) for 10 consecutive days
transcranial direct current stimulation
Patients will receive 10 sessions of 20 minutes of 1.5 mA electrical stimulation on consecutive days
Placebo
Patients will receive placebo tablet (Galenus pharmaceutical company)
sham transcranial direct current stimulation
Patients will receive 10 sessions of 20 minutes of sham electrical stimulation on consecutive days
The National Brain Mapping Laboratory (NBML), Tehran
Ardabil University of Medical Sciences
OTHER
Leibniz Research Centre for Working Environment and Human Factors
OTHER
University of Tehran
OTHER
The National Brain Mapping Laboratory (NBML)
OTHER